Several other equities analysts have also recently commented on CERC. LADENBURG THALM/SH SH reissued a buy rating and issued a $8.00 price target on shares of Cerecor in a research report on Tuesday, July 2nd. Maxim Group reissued a buy rating and issued a $10.00 price target on shares of Cerecor in a research report on Tuesday, July 2nd. HC Wainwright set a $11.00 price target on shares of Cerecor and gave the company a buy rating in a research report on Monday, July 15th. Finally, TheStreet cut shares of Cerecor from a c- rating to a d+ rating in a research report on Wednesday, May 29th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of Buy and an average price target of $9.67.
Shares of NASDAQ:CERC traded down $0.11 during mid-day trading on Thursday, reaching $3.61. 137,814 shares of the company were exchanged, compared to its average volume of 66,180. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.91 and a current ratio of 0.95. The company has a 50-day moving average price of $4.91. Cerecor has a 1 year low of $2.71 and a 1 year high of $7.65.
In other news, Director Armistice Capital, Llc acquired 12,587 shares of Cerecor stock in a transaction dated Monday, May 13th. The shares were acquired at an average cost of $4.85 per share, for a total transaction of $61,046.95. The acquisition was disclosed in a document filed with the SEC, which is available at this link. Also, major shareholder Armistice Capital Master Fund acquired 51,000 shares of Cerecor stock in a transaction dated Friday, May 31st. The stock was purchased at an average price of $4.71 per share, for a total transaction of $240,210.00. The disclosure for this purchase can be found here. Insiders acquired a total of 225,219 shares of company stock valued at $1,077,864 in the last three months. 64.30% of the stock is currently owned by corporate insiders.
Institutional investors and hedge funds have recently made changes to their positions in the company. Tibra Equities Europe Ltd acquired a new stake in shares of Cerecor in the 1st quarter valued at $210,000. BlackRock Inc. raised its holdings in shares of Cerecor by 18.5% in the 4th quarter. BlackRock Inc. now owns 33,960 shares of the company’s stock valued at $109,000 after purchasing an additional 5,293 shares in the last quarter. Virtu Financial LLC acquired a new stake in shares of Cerecor in the 1st quarter valued at $109,000. Spark Investment Management LLC raised its holdings in shares of Cerecor by 60.5% in the 1st quarter. Spark Investment Management LLC now owns 83,000 shares of the company’s stock valued at $484,000 after purchasing an additional 31,290 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in shares of Cerecor by 50.7% in the 4th quarter. Geode Capital Management LLC now owns 94,990 shares of the company’s stock valued at $306,000 after purchasing an additional 31,951 shares in the last quarter. Institutional investors and hedge funds own 53.90% of the company’s stock.
Cerecor Inc, a pharmaceutical company, focuses on pediatric health care. Its lead product portfolio includes prescribed dietary supplements, such as Poly-Vi-Flor and Tri-Vi-Flor; and prescription drugs, such as Millipre, Ulesfia, Karbinal ER, AcipHex Sprinkle, and Cefaclor for oral suspension, as well as Flexichamber a medical device.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Cerecor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerecor and related companies with MarketBeat.com's FREE daily email newsletter.